InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,307.01
(
-0.27%
)
US TECH 100
18,307.16
(
0.41%
)
Dow Jones
39,671.04
(
-0.51%
)
Brent Oil
81.48
(
-0.07%
)
Bitcoin
69,460.00
(
0.52%
)
Post# of 8478
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TheBigWhale

Send PM Follow Ignore
Followers 8
Posts 184
Boards Moderated 0
Alias Born 02/10/2017

TheBigWhale

Re: None

Wednesday, 03/06/2019 12:29:43 PM

Wednesday, March 06, 2019 12:29:43 PM

Post# of 8478
By Michael Dabaie

Novavax Inc. (NVAX) shares were down 67% to 70 cents in heavy volume Thursday after a study missed its primary objective.

The late stage biotechnology company said earlier that a global Phase 3 clinical trial of ResVax to prevent respiratory syncytial virus in infants didn't meet primary objective of prevention of medically significant RSV lower respiratory tract infection.

The trial showed efficacy against a secondary objective on RSV LRTI hospitalization.

The company said its next step is to meet with regulatory authorities to discuss licensure pathways.

The study is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

February 28, 2019 13:25 ET (18:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NVAX News
More NVAX News
InvestorsHub NewsWire

Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM

"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

Start posting your company's news
Only $200 per official company press release!